H.C.
The post H.C. Wainwright Reaffirms Their Buy Rating on Fulcrum Therapeutics (FULC) appeared first on Smarter Analyst.
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Fulcrum Therapeutics (FULC) today and set a price target of $20.00. The companys shares closed last Thursday at $...
https://www.smarteranalyst.com/new-blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-fulcrum-therapeutics-fulc/#SmarterAnalyst
Sinun täytyy kirjautua sisään ennen kuin voit kommentoida.